Key Points Merck is seeking ways to prepare for a significant upcoming patent cliff.The company has just announced another ...

Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the ...

Backed by an initial funding of $15 million from the National Science Foundation, the Regenerative Medicine Engine is the ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

U.S. appetite for U.K. companies is only intestifying in 2025; here, Law.com charts some of the highest profile deals in H1, ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...